gms | German Medical Science

57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

German Society for Neuropathology and Neuroanatomy

12. - 15.09.2012, Erlangen

57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)

BRAF V600E immunohistochemistry in the diagnosis of Pleomorphic xanthoastrocyomas and Gangliogliomas

Meeting Abstract

  • presenting/speaker Christian Kölsche - Ruprecht-Karls-Universität Heidelberg, Department of Neuropathology, Heidelberg, Germany; German Cancer Research Center (DKFZ), Clinical Cooperation Unit Neuropathology, Heidelberg, Germany
  • Jens Schittenhelm - University of Tübingen, Department of Neuropathology, Institute of Pathology and Neuropathology, Tübingen, Germany
  • Adelheid Wöhrer - Medical University of Vienna, Institut of Neurology, Vienna, Austria
  • Astrid Jeibmann - University Hospital Münster, Department of Neuropathology, Münster, Germany
  • Patricia Kohlhof - Klinikum Stuttgart, Katharinenhospital, Department of Pathology, Stuttgart, Germany
  • Matthias Preusser - Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria; Medical University of Vienna, Department of Medicine I, Vienna, Austria
  • Andreas von Deimling - Ruprecht-Karls-Universität Heidelberg, Department of Neuropathology, Heidelberg, Germany; German Cancer Research Center (DKFZ), Clinical Cooperation Unit Neuropathology, Heidelberg, Germany
  • David Capper - Ruprecht-Karls-Universität Heidelberg, Department of Neuropathology, Heidelberg, Germany; German Cancer Research Center (DKFZ), Clinical Cooperation Unit Neuropathology, Heidelberg, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Erlangen, 12.-15.09.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12dgnnPP3.30

DOI: 10.3205/12dgnn074, URN: urn:nbn:de:0183-12dgnn0743

Published: September 11, 2012

© 2012 Kölsche et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

In the present study, we investigated a series of 33 PXA and 73 GG, as well as 29 Glioblastomas (GBM) and 13 supratentorial pilocytic astrocytomas (PA) as control cases by immunohistochemistry (IHC) using a previously described BRAF V600E mutation specific monoclonal antibody (clone VE1). VE1 specificity was verified by direct sequencing of BRAF in all cases. All cases of PXA and GG were additionally characterized for histological features and expression of other commonly used diagnostic markers (CD34, Synaptophysin and GFAP). VE1 immunohistochemistry was positive in 19/33 (58%) PXA, 41/73 (56%) GG, 0/29 (0%) GBM and 1/13 (8%) PA. DNA sequencing confirmed VE1 staining results in 100% of PXAs, 91% of GGs, 100% of GBMs and 100% of PAI. The morphological analysis of the series is currently ongoing. Preliminary results indicate that histological features are not markedly different between BRAF wild type and BRAF mutated tumors. Interestingly, GG that are supposed to represent well delineated lesion, presented with diffuse infiltration of VE1 positive ganglionic cells in several instances.

Our data confirm the high prevalence of BRAF (V600E) mutation in PXA and indicate that previously the BRAF mutation rate in GG was likely underestimated. Our data further substantiates the suitability of VE1 as an ancillary diagnostic marker in PXA and GG, especially for the differentiation of such lesions from other tumors like GBM or PA.